Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dexter Yan

Senior Reporter

Shanghai-based Dexter Yan is a senior writer covering Chinas surging pharma industry on the APAC Pharma news team. With a keen interest in commercial activities taking place around the clock, he is always on the lookout for opportunities to keep readers better informed of any developments in the field.

Latest From Dexter Yan

New Modalities Help Chinese Biotechs Win Investors’ Attention

Five Chinese bioventures have raised more than $70m from venture capital and private equity funds since late May.

China Financing

Drought Ending? Shanghai’s STAR Market Considers Two IPO Applicants

With the first half of 2022 ending, two Chinese developers of innovative drugs - antibody specialist Chongqing Genrix Biopharmaceutical and Suzhou Teligene, which focuses on small molecules, are looking to go public on Shanghai’s STAR Market, ending a recent drought of biopharma listings.

China Financing

China Tweaks On-Site Inspection Priorities As Registration Filings Soar

China’s Center for Drug Evaluation has introduced a risk-based process to initiate on-site inspections related to drug registrations. It is hoped the novel system will suit the current capacity of auditor teams against a backdrop of an ongoing spike in product approval applications in the country since 2019.

China Clinical Trials

China Oncology Drug Innovation Not Correlating With Clinical Benefit

While China approved a record number of innovative oncology drugs in 2021, the correlation between their novel mechanisms of action or targeted indication and clinical benefit is not statistically insignificant, a well-known researcher claims in a new report.

China Cancer

Biotechs Stage No-Show As China’s STAR Market Marks Third Anniversary

To date this year, not a single innovative drug-focused biotech has filed for an initial public offering on the Science and Technology Innovation Board of the Shanghai Stock Exchange. Apart from a suspected tightening of listing rules, IPO disclosures and the plummeting share prices of public companies seem to be looming large over bioventures aiming considering floating on the bourse.

China Financing

Can China Innovate? Degron Aims For First-In-Class TPD Therapies

Fresh out of an impressive new round of financing and armed with $32m, Shanghai's Degron Therapeutics is aiming for nothing but first-in-class treatments. Its co-founder and CSO shares views on creating original innovative drugs from inside China in an exclusive interview with Scrip.

China Research & Development
See All
UsernamePublicRestriction

Register